Your AI-Trained Oncology Knowledge Connection!

Advancing Treatment for NRG1 Fusion+ Lung and Pancreatic Cancers : Episode 2

Commentary

Video

April 29, 2024

Differences Between DNA and RNA Testing for NRG1

Author(s):

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses differences between DNA and RNA fusions for detecting NRG1 fusions.

EP: 1.Prevalence of NRG1 Fusions in Lung Cancer

Now Viewing

EP: 2.Differences Between DNA and RNA Testing for NRG1

EP: 3.Standard Treatments for NRG1 Fusion+ NSCLC

EP: 4.Ongoing Research Efforts Targeting NRG1 in Lung Cancer

EP: 5.Efficacy With NRG1-Directed Agents in NSCLC

EP: 6.Prognosis, Rarity of NRG1+ Pancreatic Cancer

EP: 7.Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer

EP: 8.Standard Treatment Regimens for NRG1+ Pancreatic Cancer

EP: 9.Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer

EP: 10.Current Approaches and Treatment Challenges in NRG1+ NSCLC and Pancreatic Cancer

EP: 11.DNA vs RNA Sequencing in NSCLC and Pancreatic Cancer

EP: 12.A Physician Assistant's Perspective: Treatment Planning in NRG1+ NSCLC and Pancreatic Cancer

EP: 13.The Potential Role for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

EP: 14.Using a Multidisciplinary Treatment Approach in NRG1+ NSCLC and Pancreatic Cancer

EP: 15.Harnessing the Ability to Target NRG1 Fusions in NSCLC, Pancreatic Cancer

EP: 16.The Role of RNA in Detecting NRG1 and Other Fusions in Solid Tumors

EP: 17.The Pathologist’s Role in Molecular Testing in NSCLC, Pancreatic Cancer

EP: 18.Using a Multidisciplinary Approach in NRG1+ NSCLC, Pancreatic Cancer

EP: 19.Overcoming Challenges With Molecular Testing in NSCLC, Other Solid Tumors

EP: 20.NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity

Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity

Latest Conference Coverage

Oncology Experts Preview Top Abstracts From AUA 2025

Future of Bispecifics and CAR T in R/R MM

Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Differences Between DNA and RNA Testing for NRG1

EP: 1.Prevalence of NRG1 Fusions in Lung Cancer

EP: 2.Differences Between DNA and RNA Testing for NRG1

EP: 3.Standard Treatments for NRG1 Fusion+ NSCLC

EP: 4.Ongoing Research Efforts Targeting NRG1 in Lung Cancer

EP: 5.Efficacy With NRG1-Directed Agents in NSCLC

EP: 6.Prognosis, Rarity of NRG1+ Pancreatic Cancer

EP: 7.Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer

EP: 8.Standard Treatment Regimens for NRG1+ Pancreatic Cancer

EP: 9.Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer

EP: 10.Current Approaches and Treatment Challenges in NRG1+ NSCLC and Pancreatic Cancer

EP: 11.DNA vs RNA Sequencing in NSCLC and Pancreatic Cancer

EP: 12.A Physician Assistant's Perspective: Treatment Planning in NRG1+ NSCLC and Pancreatic Cancer

EP: 13.The Potential Role for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

EP: 14.Using a Multidisciplinary Treatment Approach in NRG1+ NSCLC and Pancreatic Cancer

EP: 15.Harnessing the Ability to Target NRG1 Fusions in NSCLC, Pancreatic Cancer

EP: 16.The Role of RNA in Detecting NRG1 and Other Fusions in Solid Tumors

EP: 17.The Pathologist’s Role in Molecular Testing in NSCLC, Pancreatic Cancer

EP: 18.Using a Multidisciplinary Approach in NRG1+ NSCLC, Pancreatic Cancer

EP: 19.Overcoming Challenges With Molecular Testing in NSCLC, Other Solid Tumors

EP: 20.NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers

Newsletter

Latest CME

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Latest Conference Coverage